In-depth analysis of long-term clinical trial data provides important insights for doctors treating…
Anti-PD-1 checkpoint antibody is the only immunotherapy approved for first-line treatment for lung cancer patients.
Anti-PD-L1 atezolizumab is the second PD-1 pathway drug approved for lung cancer this month.
Patients with metastatic non-small cell lung cancer could soon have a new first-line immunotherapy treatment option.
Combination checkpoints, improved CAR T cells show promise.
Nivolumab, a PD-1 immunotherapy, is now approved as second-line therapy for the most common type of lung…
Patients with non-small cell lung cancer may now receive a PD-1 immunotherapy as second-line treatment after chemotherapy.
Join us on August 21 as Julie Brahmer, MD, discusses the latest research and current treatments for…
Patients with lung cancer will soon be able to receive immunotherapy as first-line treatment on an experimental…
